Virpax Pharmaceuticals Stock Cash Flow From Operations
| VRPXDelisted Stock | USD 0.25 0.04 19.05% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Virpax Pharmaceuticals' long-term financial health and intrinsic value.
Virpax |
Virpax Pharmaceuticals Company Cash Flow From Operations Analysis
Virpax Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Virpax Pharmaceuticals Cash Flow From Operations | (16.71 B) |
Most of Virpax Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Virpax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Virpax Pharmaceuticals has (16.71 Billion) in Cash Flow From Operations. This is 3269.72% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is significantly higher than that of the company.
Virpax Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Virpax Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Virpax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Virpax Pharmaceuticals by comparing valuation metrics of similar companies.Virpax Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Virpax Fundamentals
| Return On Equity | -23.65 | ||||
| Return On Asset | -1.35 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.24 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 0.41 % | ||||
| Number Of Shares Shorted | 577.07 K | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (12.08 B) | ||||
| Net Income | (12.07 B) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 2.47 B | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | (1.53) X | ||||
| Cash Flow From Operations | (16.71 B) | ||||
| Short Ratio | 0.04 X | ||||
| Earnings Per Share | (71.00) X | ||||
| Target Price | 3.0 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 831.85 K | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (71.61 B) | ||||
| Working Capital | (913.76 K) | ||||
| Net Asset | 1.56 B |
About Virpax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virpax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virpax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Virpax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Virpax Pink Sheet
If you are still planning to invest in Virpax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Virpax Pharmaceuticals' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |